Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convectionenhanced delivery (CED) for recurrent malignant glioma (MG)

Authors
Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 7d1ab981b4f907de099072a0bde56138b1821f18
First added on: Feb 12, 2025